Outlook Therapeutics, Inc. (NASDAQ:OTLK) Short Interest Update

Outlook Therapeutics, Inc. (NASDAQ:OTLK) was the target of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 1,660,000 shares, an increase of 24.8% from the May 15th total of 1,330,000 shares. Based on an average trading volume of 704,700 shares, the short-interest ratio is currently 2.4 days. Approximately 10.0% of the company’s stock are sold short.

Outlook Therapeutics Price Performance

Shares of NASDAQ OTLK opened at $7.67 on Monday. Outlook Therapeutics has a 12-month low of $4.00 and a 12-month high of $37.20. The company’s fifty day simple moving average is $7.99 and its 200 day simple moving average is $8.20.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.67). As a group, sell-side analysts forecast that Outlook Therapeutics will post -4.02 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. BTIG Research upgraded shares of Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $50.00 price objective on the stock in a report on Wednesday, March 27th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Outlook Therapeutics in a research note on Friday, May 17th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $46.43.

Institutional Investors Weigh In On Outlook Therapeutics

An institutional investor recently raised its position in Outlook Therapeutics stock. Scotia Capital Inc. increased its position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) by 420.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 338,439 shares of the company’s stock after buying an additional 273,463 shares during the quarter. Scotia Capital Inc. owned 0.13% of Outlook Therapeutics worth $75,000 as of its most recent filing with the Securities & Exchange Commission. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.